Caoibhne McSweeney

Caoibhne McSweeney

Auto-generated profile, based on publicly available information

Caoibhne McSweeney

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
RLRenyan Liu
Renyan Liu
XWXin Wang
Xin Wang
TBTimothy B. Branigan
Timothy B. Branigan
DGDaryl Griffin
Daryl Griffin
CMCaoibhne McSweeney
Caoibhne McSweeney
GSGeoffrey I. Shapiro
Geoffrey I. Shapiro
Purpose: CDK6 overexpression is one critical determinant of acquired CDK4/6 inhibitor resistance. Because BRD4 is recruited to the CDK6 promoter, we investigated the potential of bromodomain and extraterminal domain (BET) inhibition to reverse CDK4/6 inhibitor resistance. Experimental Design: Cell viability and survival assays and cell line xenografts were used to evaluate BET inhibition in palbociclib-resistant breast cancer cells. Vehicle- and BET inhibitor–treated cells were subjected to RNA sequencing. CDK6 promoter activity was assessed with luciferase assays, and the miRPathDB version 2.0 database was used to identify potential miRNA mediating the effects of BET inhibition. Experiments were conducted to determine whether continued palbociclib treatment is essential for BET inhibitor efficacy and to explore associated mechanisms. Results: In CDK4/6 inhibitor–resistant models overexpressing CDK6, a cell-cycle gene signature was differentially downregulated following BET inhibition. The BET inhibitors JQ1 and ZEN-3694 reduced the expression of CDK6 and cyclin D1, reinstated CDK4/6 inhibitor–induced cell-cycle arrest, and triggered apoptosis in vitro, as well as tumor regression in vivo. Mechanistically, BET inhibition downregulated CDK6 expression through the induction of miR-34a-5p, rather than by directly repressing the CDK6 promoter. Introduction of a miR-34a-5p inhibitor abrogated BET inhibitor–mediated molecular changes, whereas a miR-34a-5p mimic replicated the effects of BET inhibition. Lastly, resistant cells exhibited downregulation of BCL-2 in the presence of continued palbociclib, associated with reduced estrogen receptor alpha expression, facilitating sensitivity to BET inhibition. Conclusions: Our findings highlight BET inhibition or the application of miR-34a-5p mimics as promising strategies to reverse CDK4/6 inhibitor resistance in a subset of ER+ breast cancers.

1 December 2025
Verified
Other
Open access
PDF file
RLRenyan Liu
Renyan Liu
XWXin Wang
Xin Wang
TBTimothy B. Branigan
Timothy B. Branigan
DGDaryl Griffin
Daryl Griffin
CMCaoibhne McSweeney
Caoibhne McSweeney
GSGeoffrey I. Shapiro
Geoffrey I. Shapiro
BET inhibition reverses palbociclib resistance.

1 December 2025
Verified
Other
Open access
PDF file
RLRenyan Liu
Renyan Liu
XWXin Wang
Xin Wang
TBTimothy B. Branigan
Timothy B. Branigan
DGDaryl Griffin
Daryl Griffin
CMCaoibhne McSweeney
Caoibhne McSweeney
GSGeoffrey I. Shapiro
Geoffrey I. Shapiro
BET inhibition induces molecular changes that contribute to cell cycle arrest and growth suppression.

1 December 2025
Verified
Other
Open access
PDF file
RLRenyan Liu
Renyan Liu
XWXin Wang
Xin Wang
TBTimothy B. Branigan
Timothy B. Branigan
DGDaryl Griffin
Daryl Griffin
CMCaoibhne McSweeney
Caoibhne McSweeney
GSGeoffrey I. Shapiro
Geoffrey I. Shapiro
Identification of miR-34a-5p but not miR-34a-3p as a key miRNA mediating the effect of JQ1 on palbociclib-resistant cells.

1 December 2025
Verified
Other
Open access
PDF file
RLRenyan Liu
Renyan Liu
XWXin Wang
Xin Wang
TBTimothy B. Branigan
Timothy B. Branigan
DGDaryl Griffin
Daryl Griffin
CMCaoibhne McSweeney
Caoibhne McSweeney
GSGeoffrey I. Shapiro
Geoffrey I. Shapiro
BET inhibition induces apoptosis, cell cycle arrest, and senescence in palbociclib-resistant cells.

1 December 2025
Verified
Other
Open access
PDF file
RLRenyan Liu
Renyan Liu
XWXin Wang
Xin Wang
TBTimothy B. Branigan
Timothy B. Branigan
DGDaryl Griffin
Daryl Griffin
CMCaoibhne McSweeney
Caoibhne McSweeney
GSGeoffrey I. Shapiro
Geoffrey I. Shapiro
Palbociclib downregulates BCL-2 and sensitizes cells to JQ1.